BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

Cash, cash equivalents, and short-term investments of $113.1 million as of December 31, 2024, extend operational runway into the first quarter of 2026. Completion of enrollment in the ENERGY 3 pivotal ...

The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin immunoprecipitation ...

After a thorough strategic review, Spok is reducing operating expenses, delivering in excess of $6.0 million in anticipated annual cost savings, along with an approximately 10% workforce reduction.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry ...

Spread the love“`html When it comes to product development, prioritizing product features can make or break the success of your offering. With countless tasks and requests vying for your attention, ...

Douglas, a technical analyst, came to me having gained extensive experience within a niche market, seeking to transition into an analyst or market research role. He had developed a two-page resume ...